AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that it has initiated patient enrollment in a multi-center Phase 2 exploratory biomarker study of tivozanib, its lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, in patients with renal cell carcinoma (RCC).
"I must reluctantly conclude that Congress exceeded the bounds of its authority in passing the act with the individual mandate," the judge said.
Researchers at the National Institutes of Health and the University of Hong Kong have discovered that high levels of a particular protein in cancer cells are a reliable indicator that a cancer will spread.
$50 donation by the bank when you first use the card and ongoing contributions.
In an audacious twist on the concept of fighting fire with fire, scientists have developed a provocative strategy of fighting cancer with cancer.
New Facebook Group chats Tuesday evenings
A daily news feed, compiled from a Twitter list, for cancer advocates.
|NeonCRM by Neon One|